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ABSTRACT	
Background	This	study	aimed	to	investigate	whether	adjunctive	inspiratory	muscle	training	(IMT)	can	
enhance	the	well-established	benefits	of	pulmonary	rehabilitation	(PR)	in	COPD	patients.		
Methods	 219	 COPD	 patients	 (FEV1:	 42±16%	 predicted)	 with	 inspiratory	 muscle	 weakness	 (PImax:	
51±15	 cmH2O)	were	 randomised	 into	 an	 intervention	 group	 (IMT	 +	 PR;	 n=110)	 or	 a	 control	 group	
(Sham-IMT	+	PR;	n=109)	 in	this	double	blind,	multicentre	RCT	between	February	2012	and	October	
2016	 (ClinicalTrials.gov	NCT01397396).	 Improvement	 in	six-minute	walking	distance	 (6MWD)	was	a	
priori	defined	as	the	primary	outcome.	Pre-specified	secondary	outcomes	included	respiratory	muscle	
function	and	endurance	cycling	time.	
Findings	 No	 significant	 differences	 between	 the	 intervention	 group	 (n=89)	 and	 the	 control	 group	
(n=85)	 in	 improvements	 in	6MWD	were	observed	 (0.3m,	95%CI:	 -13	 to	14;	p=0.967).	Patients	who	
completed	assessments	in	the	intervention	group	achieved	larger	gains	in	inspiratory	muscle	strength	
(effect	 size:	 1.07,	 p<0.001)	 and	 endurance	 (effect	 size:	 0.79,	 p<0.001)	 than	 patients	 in	 the	 control	
group.	75	seconds	additional	improvement	in	endurance	cycling	time	(95%CI:	1	to	149,	p=0.048)	and	
significant	reductions	in	Borg	dyspnoea	score	at	iso-time	during	the	cycling	test	(95%CI:	-1.5	to	-0.01;	
p=0.049)	were	observed	in	the	intervention	group.	
Interpretation	Improvements	in	respiratory	muscle	function	after	adjunctive	IMT	did	not	translate	into	
additional	 improvements	 in	 6MWD	 (primary	 outcome).	 Additional	 gains	 in	 endurance	 time	 and	
reductions	 in	 symptoms	 of	 dyspnea	 were	 observed	 during	 an	 endurance-cycling	 test	 (secondary	
outcome).	
Key	words:	chronic	obstructive	pulmonary	disease,	respiratory	muscles,	inspiratory	muscle	training,	
exercise	capacity,	dyspnoea	
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KEY	MESSAGES	
• What	is	the	key	question?	
Can	adjunctive	inspiratory	muscle	training	(IMT)	enhance	the	well-established	benefits	of	pulmonary	
rehabilitation	(PR)	in	selected	COPD	patients	with	inspiratory	muscle	weakness?		
• What	is	the	bottom	line?	
Improvements	in	respiratory	muscle	function	beyond	those	induced	by	general	exercise	training	did	
not	result	in	additional	improvements	in	6-minute	walking	distance	(primary	outcome).	
• Why	read	on?	
The	observed	between	group	difference	in	endurance	cycling	time	could	serve	as	a	basis	for	sample	
size	calculations	using	endurance	tests	as	primary	outcomes	in	future	studies	of	adjunct	interventions.	 	
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INTRODUCTION	
Chronic	Obstructive	Pulmonary	Disease	(COPD)	 is	a	major	cause	of	chronic	morbidity	and	mortality	
worldwide.[1]	Respiratory	muscle	dysfunction,	which	is	frequently	observed	in	COPD	patients,[2]	plays	
a	key	role	in	the	perception	of	dyspnea[3,	4]	and	contributes	to	exercise	intolerance	in	these	patients.	
[5,	6]	
Pulmonary	rehabilitation	(PR)	is	standard	care	for	COPD	patients	and	results	in	statistically	significant	
and	 clinically	 relevant	 improvements	 in	 exercise	 capacity	 and	 health-related	 quality	 of	 life.[7,	 8]	
Inspiratory	muscle	 training	 (IMT)	has	been	extensively	 studied	 in	 the	 last	 decades	 in	patients	with	
COPD.[9]	 However,	 due	 to	 differing	 interpretations	 of	 the	 existing	 evidence,	 in	 combination	 with	
limited	resources	and	time	constraints	during	PR	programme,	this	adjunctive	therapy	is	at	this	moment	
not	 included	 in	 about	 50%	 of	 these	 programmes.[9-14]	 IMT	 as	 a	 standalone	 therapy	 improves	
inspiratory	 muscle	 function	 (strength	 and	 endurance),	 decreases	 symptoms	 of	 dyspnoea,	 and	
improves	exercise	capacity.[9]	The	value	of	adjunctive	IMT	during	PR	is	less	clear.	While	adjunctive	IMT	
in	combination	with	GET	resulted	in	significant	additional	improvements	in	respiratory	muscle	function	
beyond	 the	 effects	 of	GET	 alone,	 its	 additional	 effects	 on	 outcomes	 such	 as	 exercise	 capacity	 and	
quality	of	life	are	insufficiently	supported	by	data	so	far.[7,	9]	Based	on	subgroup	analyses	in	meta-
analyses	 and	general	 physiological	 considerations	 it	 has	been	 recommended	 that	 future	 studies	of	
adjunctive	 IMT	 in	 patients	 with	 COPD	 should	 focus	 specifically	 on	 patients	 with	 exercise	 induced	
dyspnea	and	inspiratory	muscle	weakness.[7,	9,	15]		
The	 present	 study	 examined	 the	 effects	 of	 adding	 a	 largely	 unsupervised,	 but	 well-controlled	
adjunctive	 IMT	 programme	 in	 the	 context	 of	 an	 adequately	 powered,	 multicentre,	 double-blind,	
randomised	controlled	trial	design,	in	selected	COPD	patients	with	inspiratory	muscle	weakness.	We	
wanted	to	answer	 the	question	whether	 IMT	can	be	a	useful	adjunctive	 therapy	during	pulmonary	
rehabilitation	for	patients	with	COPD.	We	hypothesised	that	adjunctive	IMT	would	result	in	additional	
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improvements	 in	 functional	 exercise	 capacity	 (primary	 outcome)	 and	 inspiratory	 muscle	 function	
compared	to	rehabilitation	alone.	
	
METHODS	
The	 study	 was	 approved	 centrally	 by	 the	 University	 Hospital	 Leuven’s	 Institutional	 Review	 Board	
(Approval	 Number	 ML7489)	 as	 well	 as	 from	 all	 other	 relevant	 local	 centre	 committees	 and	 was	
registered	in	an	international	trial	registry	database	(clinicaltrials.gov:	NCT01397396).	Clinically	stable	
COPD	patients	with	reduced	maximal	inspiratory	mouth	pressure	(PImax	<60	cmH2O	or	<50%	of	the	
predicted	normal	value)	participated	in	the	study	between	February	2012	and	October	2016	[9].	
More	 information	about	study	procedures	can	be	 found	 in	an	extended	MATERIAL	AND	METHODS	
section	and	in	a	video	tutorial	(see	supplementary	video	files	1,	2,	3,	and	4),	as	well	as	in	a	previously	
published	study	protocol.[16]	
Interventions.	Both	groups	performed	an	 identical	general	exercise	 training	 (GET)	programme.	The	
training	volume	ranged	from	20	sessions	(Germany),	to	36	sessions	(other	centres).	Training	frequency	
ranged	from	three	to	five	sessions	per	week.	Duration	of	training	sessions	was	around	60	minutes.	
Patients	performed	endurance	 training	or	 interval	 training	at	moderate	 to	high	 intensities	Training	
intensities	during	GET	were	progressively	 increased	during	 the	course	of	 the	programme	based	on	
symptom	scores.	Training	 intensities	corresponded	to	Borg	CR-10	Scale	ratings	of	4–6	on	dyspnoea	
sensation.[16]	 Physiotherapists	 providing	 this	 intervention	 were	 blinded	 to	 group	 allocation	 of	
patients.	All	participants	(intervention	and	control	group)	were	led	to	believe	that	they	followed	an	
active	adjunctive	 IMT	 intervention	during	 the	GET	 intervention.	This	was	done	 in	order	 to	 improve	
adherence	with	the	intervention	in	the	control	group	and	to	ensure	placebo	treatment	effects	in	both	
groups.[17]	 IMT	 in	 both	 groups	 was	 performed	 daily,	 using	 the	 PowerBreathe	 KHP2	 device	
(POWERbreathe®KHP2,	 HaB	 International	 Ltd.,	 Southam,	 UK)	 according	 to	 previously	 described	
methods.[18]	 The	 training	 intensity	 (average	 external	 load	 (cmH2O))	 and	 training	 quality	 (average	
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mean	power	per	breath	and	total	work	of	breathing	during	one	session	of	30	breaths)	were	registered	
and	stored	during	all	training	sessions.	During	weekly	supervised	sessions	(7%	of	all	training	sessions),	
data	 on	 training	 quality	 during	 the	 unsupervised	 sessions	 were	 reviewed	 and	 patients	 received	
instructions	and	 feedback	on	how	 to	optimize	 their	home	 training	efforts.	Training	 intensity	 in	 the	
intervention	group	was	set	 initially	at	a	 load	of	approximately	50%	of	patients’	maximal	 inspiratory	
mouth	pressure	(PImax).	This	initial	load	was	then	continuously	and	gradually	increased	to	the	highest	
tolerable	intensity	during	each	of	the	supervised	sessions.[18]	Training	intensity	in	the	control	group	
was	set	at	10%	baseline	PImax	and	was	not	modified	throughout	the	intervention	period.	
Outcome	measurements.	 The	primary	outcome	six-minute	walking	distance	 (6MWD)	was	assessed	
according	 to	 a	 standardized	 published	 protocol	 and	 related	 to	 reference	 values.[19]	 Secondary	
outcomes	 included	 respiratory	muscle	 function	 (strength	 and	 endurance),	maximal	 and	 endurance	
cycling	exercise	capacity,	pulmonary	function,	limb	muscle	forces,	and	objectively	measured	physical	
activity	(DynaPort	Minimod,	McRoberts	BV,	The	Hague,	The	Netherlands).	All	outcome	assessors	were	
blinded	to	group	allocation.	
Sample	size	calculation.	To	detect	a	minimally	clinically	important	difference	between	groups	of	26m	
in	 the	 6-minute	walking	 distance	 (6MWD),[20]	 assuming	 a	 standard	 deviation	 of	 the	within	 group	
differences	in	the	6MWD	at	the	end	of	the	intervention	period	of	60	m	in	both	groups	with	a	degree	
of	certainty	(statistical	power)	of	80%	and	a	risk	for	a	type	I	error	(α)	<	5%,	minimally	85	patients	were	
calculated	to	be	included	in	each	group,	given	an	anticipated	dropout	rate	of	30%.	
Statistical	analysis.	All	data	were	analyzed	using	a	modified	intention	to	treat	approach	[SPSS	Version	
24	(IBM,	Chicago,	IL,	USA)	and	SAS	version	9.4	(SAS	Institute,	Cary,	NC,	USA)].	This	means	that	we	did	
not	 consider	 patients	 who	 had	 missing	 outcome	 data	 due	 to	 loss	 to	 follow	 up	 in	 the	 analysis.	
Consequently	no	imputation	for	missing	data	was	performed	and	a	so	called	‘complete	/	available	case	
analysis’	was	performed.[21]	The	missing	data	was	 interpreted	as	 ‘missing	at	 random’.	Differences	
between	 groups	 after	 the	 intervention	 were	 compared,	 adjusting	 for	 values	 of	 the	 respective	
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outcomes	 at	 baseline,	 using	 analysis	 of	 covariance	 (ANCOVA).[22]	 Because	 randomisation	 was	
performed	 by	 centre,	 the	 adjustment	 by	 centre	 was	 tested.	 Additional	 exploratory	 analyses	 were	
performed	 to	 study	 1)	 the	 impact	 of	 IMT	 characteristics	 on	 improvements	 in	 PImax	 and	 2)	 the	
relationship	between	improvements	in	PImax	and	GET	outcomes.	More	details	on	analyses	by	‘centre’	
and	exploratory	analyses	are	provided	 in	 the	online	data	supplement.	To	account	 for	 the	potential	
impact	of	differences	in	training	volume	between	GET	programme	offered	in	the	different	centres	on	
outcomes	we	also	tested	the	effect	of	‘centre’	on	treatment	effects	using	centre*intervention	effect.	
In	 post-hoc	 tests	 we	 subsequently	 compared	 the	 effects	 in	 the	 centre	 offering	 20	 sessions	 GET	
intervention	with	the	other	centres	offering	36	sessions.	
	
RESULTS	
Between	February	2012	and	October	2016,	998	patients	who	entered	the	rehabilitation	programme	
in	 the	different	 centres	were	 screened	 for	 study	participation.	A	diagram	 summarizing	 the	 flow	of	
participants	through	the	study	is	presented	in	Figure	1.	The	most	frequent	reason	for	non-eligibility	
was	not	meeting	the	PImax	inclusion	criteria	(73%	of	excluded	subjects).	At	the	end	of	the	study,	data	
were	available	for	the	primary	outcome	in	85%	of	subjects	from	the	intervention	group	and	83%	of	
participants	in	the	control	group.	Baseline	characteristics	of	included	patients	were	not	significantly	
different	between	the	2	groups	(Table	1).	Comparisons	between	completers	and	patients	who	were	
lost	to	follow-up	are	summarized	in	Table	E1	in	the	online	supplement.	
Changes	 in	 exercise	 capacity	 and	 GET	 progression.	 Results	 of	 different	 tests	 for	 exercise	 related	
outcomes	 are	 presented	 in	 Table	 2.	 No	 statistically	 significant	 between-group	 differences	 in	
improvements	 in	 6MWD	 (primary	 outcome)	 were	 observed.	 Endurance	 cycling	 time	 (secondary	
outcome)	improvement	was	significantly	greater	in	the	intervention	group	with	significant	reductions	
in	 dyspnoea	 symptoms	 at	 iso-time	 during	 the	 test	 (Table	 2).	 Both	 cycling	 and	 treadmill	 training	
intensities	 during	 GET	 sessions	 were	 slightly	 higher	 in	 the	 intervention	 group	 without	 reaching	
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statistical	significance	(p=0.212	and	p=0.657	for	cycling	and	treadmill	walking	respectively;	see	Figure	
E1	in	the	online	data	supplement).		
IMT	 progression.	 The	 intervention	 group	 completed	 79±4%	 of	 prescribed	 IMT	 sessions	 while	 the	
control	group	completed	81±4%	of	prescribed	sessions.	The	intervention	group	increased	their	training	
load	from	47±2%	of	their	baseline	PImax	in	the	first	week	of	training,	to	84±4%	of	their	baseline	PImax	
in	week	 12	 (see	 Figure	 E2	 in	 the	 online	 data	 supplement).	 Data	 on	 the	weekly	 sum	 of	 total	work	
performed	during	all	 IMT	sessions	(based	on	pressure	and	volume	data	recorded	and	stored	by	the	
training	devices)	is	presented	in	Figure	2.	The	average	Borg	CR-10	scale	inspiratory	effort	scores	for	
breathing	 during	 the	 final	 minute	 of	 the	 supervised	 IMT	 sessions	 were	 3.5±0.3	 and	 2.6±0.3	 for	
intervention	and	control	group,	respectively.		
Changes	 in	 respiratory	muscle	 function.	 Patients	 in	 the	 intervention	 group	 exhibited	 significantly	
larger	improvements	in	inspiratory,	but	not	expiratory	muscle	strength	in	comparison	to	the	control	
group	(Table	3).	During	the	endurance	breathing	test,	the	magnitude	of	improvement	in	time	to	the	
limit	of	tolerance,	average	mean	power	per	breath,	and	total	work	were	also	significantly	larger	in	the	
intervention	group	(Table	3).		
Changes	in	pulmonary	function,	quality	of	life	and	other	secondary	outcomes.	The	intervention	group	
exhibited	a	significantly	larger	increase	in	forced	vital	capacity	(FVC),	both	in	comparison	to	baseline	
and	to	the	control	group	(p<0.001	and	p=0.028,	respectively).	There	were	no	statistically	significant	
changes	in	other	pulmonary	function	variables	between	the	two	groups	(Table	E2).	While	both	groups	
exhibited	statistically	 significant	and	clinically	 relevant	 improvements	within	groups,	 there	were	no	
statistically	significant	differences	between	groups	in	all	domains	of	the	CRQ	(Table	E3).	Quadriceps	
and	handgrip	strength	were	also	both	significantly	improved	within	both	groups	after	training	with	no	
statistically	significant	between-group	differences.	There	was	no	statistically	significant	difference	in	
the	change	in	the	number	of	steps	per	day	within	or	between	the	two	groups	after	the	intervention.	
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Impact	 of	 centre	 on	 outcomes.	 Interactions	 between	 centres	 and	 between-group	 post-treatment	
differences	 in	 PImax	 (p=0.007),	 progression	 of	 training	 intensity	 during	 GET	 (p=0.200),	 endurance	
cycling	time	(p=0.007)	and	6MWD	(p=0.040)	were	observed.	One	of	the	centres	offering	a	36	session	
programme	(32%	of	total	inclusions)	consistently	exceeded	between	group	differences	in	the	centre	
offering	20	sessions	(36%	of	total	inclusions).	In	the	other	centres	offering	36	sessions	(combined	32%	
of	total	inclusions)	between	group	differences	in	these	outcomes	were	consistently	smaller	than	in	the	
centre	offering	a	lower	training	volume	(see	Table	E4	in	the	online	data	supplement).		
Correlates	of	improvements	in	inspiratory	muscle	strength.	Both	training	quality	indices	registered	
during	 IMT	sessions	(i.e.	 total	 inspiratory	work	performed	per	session	and	average	peak	power	per	
session)	 and	 progression	 in	 training	 intensity	 were	 significantly	 related	 to	 the	 magnitude	 of	
improvements	achieved	in	PImax	(Figure	3A-3C).	Conversely,	average	training	volume	(the	number	of	
sessions	 stored	by	 the	TFRL	devices)	was	not	 significantly	associated	with	changes	 in	PImax	 (p-for-
trend=0.129).	 In	a	stepwise	multiple	 regression	analyses	 total	work	performed	during	 IMT	sessions	
(partial	 r-square:	 0.24),	 baseline	 PImax	 (partial	 r-square:	 0.08)	 and	 training	 compliance	 (partial	 r-
square:	0.01)	were	significantly	related	to	the	improvements	in	PImax	after	training	(F(3,	139)	=	22.9,	
p<0.001,	R2=0.33).	More	detailed	results	of	 the	regression	analyses	are	provided	 in	Table	E5	 in	 the	
online	data	 supplement.	 Subsequently,	 improvements	 in	 PImax	were	 related	 to	 the	progression	 in	
cycling	training	intensity	during	the	GET	programme,	as	well	as	to	increases	in	6MWD	and	endurance	
cycling	time	after	the	training	period	(Figures	4A-4C).	
	
DISCUSSION	
This	study	is	the	first	adequately	powered	RCT	that	investigated	the	effects	of	adjunctive	inspiratory	
muscle	training	on	outcomes	beyond	respiratory	muscle	function	in	patients	with	COPD	who	had	been	
selected	based	on	the	presence	of	inspiratory	muscle	weakness.	There	was	no	statistically	significant	
difference	 between	 groups	 for	 improvements	 in	 6MWD	 (primary	 outcome).	 Patients	 in	 the	
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intervention	group	however	achieved	larger	gains	in	respiratory	muscle	function	and	also	endurance	
exercise	capacity	(pre-specified	secondary	outcome)	increased	significantly	more	in	the	intervention	
group.	 Significant	 reductions	 in	 dyspnoea	 symptoms	 at	 iso-time	 during	 the	 cycling	 test	 were	 also	
observed	in	favor	of	the	intervention	group.	
Contrary	to	our	initial	hypothesis,	larger	gains	in	respiratory	muscle	function	in	the	intervention	group	
did	not	translate	into	further	improvements	in	6MWD	compared	to	the	control	group.	Changes	in	the	
intervention	 group	 and	 the	 control	 group	 were	 both	 equally	 large	 and	 fall	 within	 the	 range	 of	 a	
minimum	clinically	important	difference	(MCID)	of	25-35m.[23]	These	findings	are	in	line	with	results	
from	 a	 recent	 systematic	 review	 of	 RCT’s	 studying	 adjunctive	 interventions	 during	 pulmonary	
rehabilitation.	 In	 this	 meta-analysis	 none	 of	 the	 studied	 adjunctive	 interventions	 (e.g.	 leg	 muscle	
strength	training,	inspiratory	muscle	training,	non-invasive	ventilation,	or	nutritional	supplementation)	
were	able	to	induce	statistically	significant	additional	improvements	in	6MWD.[24]	In	contrast	to	the	
results	of	 the	6MWD,	 significantly	 larger	 improvements	 in	 cycling	endurance	 time	and	 significantly	
greater	reductions	in	dyspnoea	symptoms	at	iso-time	were	observed	in	the	intervention	group.	The	
average	additional	improvement	in	endurance	cycling	time	of	75	seconds	falls	within	a	range	of	46	to	
105	 seconds	 that	 has	 recently	 been	 defined	 as	 a	 MCID	 for	 constant-load	 cycle	 endurance	 time	
improvements	 in	 response	 to	 pharmacological	 interventions.[25]	 The	 superior	 responsiveness	 of	
endurance	exercise	tests	 in	comparison	with	the	6	minute	walking	test	 is	 in	 line	with	several	other	
recent	reports	comparing	responses	in	these	outcome	measures	after	both	pharmacological	and	non-
pharmacological	interventions	in	patients	with	COPD.[26-28]	These	differences	are	probably	related	
to	the	different	characteristics	of	physiological	responses	elicited	by	the	two	tests.[26,	29]	In	hindsight	
we	believe	that	our	expected	between	group	difference	in	6MWD	of	26m	did	not	represent	a	realistic	
magnitude	of	between	group	differences	in	6MWD	in	studies	of	adjunct	interventions	to	PR.	Our	data	
rather	indicate	that	a	more	sensitive	outcome	(i.e.	endurance	walking	or	cycling	test)	might	be	more	
useful	 as	 a	 primary	 outcome.	 In	 the	 absence	 of	 a	 clinically	 meaningful	 difference	 for	 adjunct	
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interventions	the	magnitude	of	our	observed	between	group	differences	in	both	in	endurance	cycling	
time	and	symptoms	at	isotime	could	serve	as	a	basis	for	sample	size	calculations	using	endurance	tests	
as	primary	outcomes	in	future	studies	of	adjunct	interventions.	It	is	unlikely	that	the	type	of	analysis	
(intention	to	treat	based	on	‘complete	/	available	case	analysis’)	had	a	major	 impact	on	the	results	
since	the	 ‘completers’	of	the	study	did	not	differ	significantly	from	‘non-completers’	with	regard	to	
baseline	characteristics	that	were	identified	as	confounding	variables	(see	Tables	E1	and	E6	in	online	
supplement).		
In	 the	 current	 study	 we	 found	 23	 cmH2O	 or	 42%	 improvement	 of	 PImax	 in	 the	 intervention	
group	compared	to	9	cmH2O	or	17%	in	the	control	group.	In	a	recent	meta-analysis	the	improvements	
were	18	cmH2O	(29%)	in	the	intervention	group	and	only	5	cmH2O	(8%)	in	the	control	group.[9]	This	
resulted	in	PImax	effect	sizes	of	1.07	in	the	current	study	compared	to	0.73	in	the	meta-analysis.	The	
larger	 improvements	 in	 the	 control	 group	 (17%	 in	 our	 study	 vs	 8%	 in	 the	meta-analysis)	might	 be	
explained	 by	 the	 fact	 that	 not	 all	 control	 groups	 in	 the	meta-analysis	 performed	 a	 sham	 training	
intervention.	 Moreover	 in	 the	 current	 study	 all	 patients	 (intervention	 and	 control	 group)	 were	
maximally	familiarized	with	the	PImax	measurements	which	were	performed	every	week	during	the	
intervention	period.	The	larger	improvements	in	the	intervention	group	(42%	vs	29%)	might	be	related	
to	the	well-controlled	nature	of	the	IMT	programme	(despite	the	fact	that	it	was	not	performed	fully	
supervised).[18]	The	magnitude	of	improvements	in	PImax	is	comparable	to	previous	studies	involving	
this	IMT	protocol	in	patients	with	COPD.[18,	30]	The	large	effect	size	in	endurance	breathing	time	of	
0.79	was	somewhat	smaller	in	comparison	with	the	results	of	the	meta-analysis	(effect	size:	1.05).[9]	
This	might	again	be	partly	explained	by	the	fact	that	all	patients	in	our	study	(in	contrast	to	the	studies	
included	 in	 the	meta-analysis)	 participated	 in	 a	 sham	 control	 training.	 This	 sham	 intervention	 (i.e.	
performing	full	vital	capacity	inspirations	while	generating	high	inspiratory	flow	rates)	might	even	have	
constituted	an	endurance	type	training	stimulus	for	these	patients	in	addition	to	the	endurance	type	
training	stimulus	provided	by	the	general	exercise	training	sessions	itself.	
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Beyond	additional	improvements	in	exercise	capacity	and	symptoms	during	the	endurance	cycling	test	
and	 respiratory	 muscle	 function	 we	 did	 not	 observe	 any	 further	 improvements	 in	 quality	 of	 life	
domains	(including	dyspnoea	subscales).	It	might	be	that	the	substantial	improvements	in	quality	of	
life	 scores	 in	 the	 control	 group	 in	 response	 to	 the	 comprehensive	 rehabilitation	 intervention	were	
already	 approaching	 the	 ceiling	 effect	 for	 improvement.	 In	 analogy	with	 the	 absence	of	 additional	
improvements	in	the	6MWD	this	might	be	related	to	a	limited	sensitivity	of	the	applied	questionnaire	
(CRQ)	to	pick	up	additional	improvements	on	top	of	an	already	very	significant	and	clinically	important	
effect.	 This	might	be	 improved	 in	 future	 studies	by	using	other	potentially	more	 sensitive	dyspnea	
scales.	One	option	would	be	to	use	scales	that	are	specifically	designed	to	detect	different	gradations	
of	 change	 like	 the	 transitional	 dyspnea	 index.[31]	 Another	 excellent	 emerging	 option	 is	 the	
multidimensional	 dyspnea	 profile	 which	 can	 be	 specifically	 focused	 to	 assess	 symptoms	 during	
predefined	periods	(e.g.	at	standardized	times	during	an	exercise	test).[32]	
With	 regard	 to	 improvements	 in	 daily	 physical	 activity	we	 observed	 similar	 improvements	 in	 both	
groups.	We	know	that	physical	activity	is	a	complex	behaviour	that	is	determined	by	multiple	factors.	
A	systematic	review	demonstrated	that	large	improvements	in	exercise	capacity	and	symptoms	after	
rehabilitation	interventions	only	result	in	relatively	modest	increases	in	physical	activity	in	comparison	
with	control	groups	 in	patients	with	COPD.[33]	We	therefore	believe	that	 it	would	be	unrealistic	to	
expect	that	the	relatively	small	additional	improvements	in	endurance	exercise	capacity	and	dyspnea	
symptoms	after	adjunctive	IMT	(in	comparison	to	effects	of	PR	vs	control	groups)	would	easily	translate	
into	greater	participation	in	daily	physical	activity.	
Correlates	of	improvements	in	respiratory	muscle	function	and	impact	of	‘centre’	on	outcomes.	A	
significant	relationship	was	observed	between	the	improvements	in	PImax	and	both	training	quality	
during	 IMT	 (i.e.	 total	 inspiratory	work	 performed/session,	 average	 peak	 power/session)	 as	well	 as	
progression	of	training	intensity.	Our	results	emphasize	that	external	work	and	power	are	important	
training	 quality	 parameters	 of	 the	 training	 stimulus	 that	 is	 delivered	 to	 the	 inspiratory	 muscles.	
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Training	volume	or	compliance	(number	of	completed	training	sessions)	was	not	significantly	related	
with	the	magnitude	of	changes	in	PImax.	Interestingly,	we	found	in	a	multiple	regression	model	that	
from	all	training	variables	the	total	work	performed	(reflecting	pressure	and	volume	responses	during	
individual	sessions	in	combination	with	the	number	of	training	sessions)	was	the	strongest	predictor	
of	 improvements	 in	 PImax	 (see	 Table	 E5	 in	 the	 online	 data	 supplement).	 This	 underlines	 that	
monitoring	the	quality	of	the	training	(total	work	performed)	during	IMT	is	of	utmost	importance	to	
ensure	meaningful	training	adaptations	in	response	to	the	intervention.		
One	participating	centre	that	contributed	to	36%	of	all	inclusions	offered	a	20	session	GET	programme	
while	all	other	centres	offered	a	36	session	programme.	A	priori,	we	had	hypothesised	that	adjunctive	
effects	 in	the	centre	offering	fewer	training	sessions	would	be	smaller.	We	concluded	this	since	we	
expected	that	it	would	take	some	weeks	before	the	reductions	in	exertional	dyspnoea	induced	by	IMT	
would	result	in	higher	training	intensities	during	bicycle	and	treadmill	endurance	exercises	that	to	be	
tolerated	by	the	participants	of	the	PR	program.	Unexpectedly,	compared	with	the	centre	that	offered	
20	sessions,	those	offering	more	sessions	achieved	both	consistently	larger,	and	consistently	smaller	
between	 group	 differences	 in	 several	 relevant	 outcomes	 (i.e.	 increases	 in	 PImax,	 bicycle	 exercise	
intensity	 during	 PR	 sessions,	 6MWD	 and	 endurance	 cycling	 time	 see	 Table	 E4	 in	 the	 online	 data	
supplement)	 compared	with	 the	centre	 that	offered	20	 sessions.	The	uniformity	of	 these	data	 (i.e.	
differences	in	these	variables	were	either	consistently	larger	or	smaller)	is	in	line	with	the	presented	
relationships	between	improvements	achieved	in	PImax	on	the	one	hand	and	the	ability	to	increase	
exercise	 intensity	 during	 GET	 and	 resulting	 improvements	 in	 exercise	 capacity	 on	 the	 other	 hand	
(Figure	 4).	 From	 these	 observations,	 we	 conclude	 that	 factors	 other	 than	 the	 number	 of	 sessions	
offered	(such	as	contrasts	in	symptom	based	training	intensity	during	general	exercise	training	sessions	
between	groups)	probably	contributed	to	the	interaction	between	centre	and	training	outcomes.		
Strengths	and	Limitations.	One	of	 the	major	advantages	of	 the	 IMT	 intervention	 in	 comparison	 to	
previous	trials	was	the	ability	to	record	and	store	training	parameters	with	the	training	device.	The	
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information	of	recorded	data	from	IMT	sessions	performed	in	the	home	setting	was	used	to	provide	
patients	with	feedback	on	their	performance	during	supervised	sessions.	It	also	allowed	us	to	reduce	
the	total	volume	of	supervised	sessions	to	only	7%	of	all	training	sessions,	thereby	reducing	burden	on	
health	 care	 providers	 offering	 the	 intervention.	 Both	 groups	 had	 a	 high	 and	 similar	 IMT	 training	
compliance	(training	volume).	Good	compliance	in	the	control	group	was	probably	partly	related	to	
the	fact	that	all	patients	were	led	to	believe	that	they	were	participating	in	an	active	intervention.	Fifty-
five	percent	of	patients	in	the	intervention	group	met	the	target	training	intensity	(inspiratory	load	of	
≥50%	PImax)	already	from	the	2nd	week	of	training	and	increased	their	training	intensity	to	an	average	
of	84%	of	their	baseline	PImax	by	the	end	of	the	IMT	intervention	(see	Figure	E2	in	the	online	data	
supplement).	Moreover,	patients	 in	the	intervention	group	performed	the	IMT	sessions	at	this	high	
training	 intensity	 while	 reporting	 only	moderate	 (3.5±0.3)	 perceived	 inspiratory	 effort	 scores.	 The	
relatively	low	effort	scores	at	high	training	intensities	might	be	related	to	the	loading	characteristics	
of	the	device,	providing	an	adequate	volume	reward	with	every	inspiratory	effort.	These	factors	taken	
together	probably	contributed	to	the	good	compliance	with	the	training	protocol	in	the	intervention	
group	and	are	 in	 line	with	a	previous	study	using	a	similar	 training	protocol.[18]	The	proportion	of	
patients	who	discontinued	the	intervention	due	to	lack	of	motivation	was	similarly	small	in	both	groups	
(4%	and	5%	in	intervention	and	control	group,	respectively).	Collectively	these	observations	support	
the	clinical	feasibility	of	implementing	this	controlled,	high	intensity	adjunctive	IMT	protocol	during	a	
rehabilitation	programme	in	these	patients.		
Another	strength	of	the	study	was	that	the	physiotherapists	or	exercise	specialists	who	supervised	the	
GET	were	blinded	to	group	allocation.	Training	intensity	during	GET	was	gradually	increased	during	the	
course	of	the	programme	based	on	highest	tolerable	symptoms	assessed	with	Borg	CR-10	symptom	
scales.[34]	 The	 fact	 that	 we	 observed	 slightly	 higher	 (though	 not	 significantly	 different)	 training	
intensities	 especially	 on	 the	 bicycle	 in	 the	 intervention	 group	 are	 another	 indirect	 indication	 that	
participation	 in	 the	 IMT	 intervention	 probably	 impacted	 on	 activity	 related	 symptoms.	 Another	
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strength	of	the	study	is	that	patient	selection,	study	design,	training	methods,	and	selected	outcomes	
in	the	present	study	followed	recent	recommendations	for	this	type	of	 intervention.[7,	9,	15,	24]	A	
limitation	of	this	approach	is	that	the	results	are	only	applicable	to	a	selective	group	of	COPD	patients	
who	 have	 inspiratory	muscle	 weakness.	 This	 is	 a	minority	 of	 patients	 since	 only	 22%	 of	 all	 COPD	
patients	met	the	criteria	to	participate	in	the	study.	This	limits	the	external	validity	of	our	findings	to	
this	specific	subgroup	of	patients.	
This	was	also	the	main	reason	that	the	recruitment	period	had	to	be	extended	from	two	to	four	years.	
Given	the	absence	of	any	contrast	between	groups	on	the	primary	outcome	we	do	not	believe	that	the	
study	was	underpowered	for	the	primary	outcome	and	that	a	larger	sample	might	have	been	necessary	
to	detect	an	effect	on	6MWD.	We	rather	believe	that	different	outcomes	(i.e.	endurance	cycling	or	
walking	test)	should	be	chosen	as	a	primary	outcome	for	future	trials	of	adjunctive	interventions	during	
PR.[28]	We	do	also	not	believe	that	a	non-inferiority	trial	would	be	valuable	in	this	specific	setting	given	
the	initial	hypothesis	of	the	study.	Our	main	research	question	was	whether	adjunctive	treatments	can	
enhance	the	effectiveness	of	PR	in	selected	patients	for	functional	outcomes.	The	effectiveness	of	our	
‘control	intervention’	(PR)	on	6MWD	and	quality	of	life	has	already	repeatedly	been	demonstrated.[8]	
Clinical	relevance	for	an	individual	patient	will	eventually	depend	on	how	the	achieved	benefits	are	
valued	in	comparison	to	both	the	efforts	that	had	to	be	invested,	as	well	as	the	potential	discomfort	
associated	with	the	intervention.	Another	limitation	of	the	study	is	that	satisfaction	of	patients	with	
the	 adjunctive	 intervention	 was	 not	 directly	 assessed.	 Finally	 we	 did	 not	 perform	 serial	 IC	
measurements	 during	 exercise.	 This	 would	 have	 made	 it	 possible	 to	 	 evaluate	 whether	 1)	 these	
severely	hyperinflated	patients	did	dynamically	hyperinflate	during	exercise	breathing	and	whether	
this	might	be	a	patient	characteristic	influencing	the	intervention	effect;	and	2)	whether	the	combined	
intervention	was	able	to	modify	breathing	pattern	and	the	degree	of	dynamic	hyperinflation	during	
exercise	hyperpnoea.	These	measurements	could	be	performed	in	future	studies	and	might	facilitate	
identification	of	patients	who	are	more	or	less	likely	to	respond	to	the	adjunct	intervention.	
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Clinical	implications	and	general	conclusion	
The	results	of	this	study	do	not	support	the	addition	of	IMT	to	PR	to	further	enhance	the	6MWD.	At	
the	 same	 time	 we	 believe	 that	 the	 improvements	 in	 our	 secondary	 outcome	 (constant	 workrate	
endurance	cycling)	were	not	negligible	(50%	greater	than	rehabilitation	alone).	We	believe	that	this	is	
an	 important	 finding,	which	could	guide	 researchers	 towards	 identifying	more	appropriate	primary	
outcomes	 for	 future	 studies	 of	 adjunctive	 interventions	 to	 pulmonary	 rehabilitation.	 The	
multidimensional	 dyspnea	 profile	 [32]	 might	 be	 be	 an	 interesting	 option	 to	 assess	 differences	 in	
symptoms	 at	 standardized	 times	 during	 an	 exercise	 test.	 The	 overall	 good	 training	 compliance	
indicates	that	it	was	feasible	to	implement	this	adjunctive	IMT	intervention	on	a	relatively	large	scale.	
Across	 the	different	 centres	 it	was	 furthermore	 feasible	 to	 implement	 simple	and	 sensitive	 clinical	
assessments	of	respiratory	muscle	function	(both	strength	and	endurance).	The	study	also	highlights	
the	 benefits	 of	 closely	monitoring	 and	 controlling	 IMT	 sessions	 since	 both	 quality	 and	 intensity	 of	
training	 sessions	 were	 strongly	 associated	 with	 improvements	 in	 respiratory	 muscle	 function.	
Additionally,	 improvements	 in	 PImax	 were	 related	 to	 the	 progression	 in	 cycling	 training	 intensity	
during	the	GET	programme,	as	well	as	 to	 increases	 in	6MWD	and	endurance	cycling	time	after	 the	
training	period.	
We	 also	 believe	 that	 (in	 addition	 to	 using	 endurance	 exercise	 tests	 as	 primary	 outcomes)	 patient	
satisfaction	with	adjunctive	interventions	should	be	included	as	an	additional	important	outcome	in	
similar	studies	in	the	future.	 	
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Tables	
Table	1	Baseline	characteristics	of	patients	
Variables	 Intervention	group		(n=110)	 Control	group	(n=109)	
Age	(yr)	 66±8	 65±7	
Gender	(F/M)	 58/52	 66/43	
BMI	(kg/m2)	 25±6	 24±6	
FEV1	(%predicted)	 40±15	 43±17	
FVC	(%predicted)	 70±19	 77±23	
FEV1/FVC	(%)	 45±14	 45±13	
TLC	(%predicted)	 123±25	 124±24	
FRC	(%predicted)	 180±47	 179±44	
RV	(%predicted)	 213±64	 206±70	
DLCO	(%predicted)	 42±19	 41±21	
PImax	(cmH20)	 52±14	 51±12	
PImax	(%predicted)	 51±15	 52±14	
Endurance	breathing	time	(sec)	 243±109	 242±93	
Inspiratory	load	(%PImax)	 56±12	 56±15	
Peak	VO2	(%predicted)	 66±28	 63±26	
Peak	work	rate	(%predicted)	 45±25	 45±22	
Endurance	cycle	time	(sec)	 262±124	 287±159	
6MWD	(m)	 346±118	 355±104	
6MWD	(%predicted)	 56±20	 57±18	
Quadriceps	strength	(%predicted)	 70±23	 81±36	
Hand	grip	strength	(%predicted)	 87±24	 88±25	
PA	(steps/day)	 3679±2234	 4238±1853	
CRQ	dyspnoea	 15±6	 15±5	
mMRC	 2.5±1.2	 2.6±1.0	
Data	are	presented	as	mean	±	SD.	Abbreviations:	BMI	=	body	mass	index;	FEV1	=	forced	expiratory	volume	in	one	second;	FVC	
=	forced	vital	capacity;	TLC=	total	lung	capacity;	FRC	=	functional	residual	capacity;	RV	=	residual	volume;	DLCO	=		diffusing	
capacity	of	the	lungs	for	carbon	monoxide;	PImax	=	maximal	inspiratory	mouth	pressure;	Peak	VO2	=	peak	oxygen	uptake;	
Peak	 work	 rate	 =	 peak	 power	 output	 during	 a	maximal	 incremental	 cycle	 ergometry	 test;	 6MWD	 =	 six	minute	 walking	
distance;	 PA	 =	 physical	 activity;	 CRQ	 =	 chronic	 respiratory	 questionnaire;	 mMRC	 =	 modified	 Medical	 Research	 Council	
dyspnoea;	%pred	=	percentage	of	the	predicted	value	 	
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Table	2	Changes	in	exercise-related	outcomes	
Variables	
Pre-		
training	
Post-
training	
Pre-
training	
Post-
training	
Adjusted	
difference	(95%	CI)	
at	Post-training	
p-
value*	Functional	exercise	
capacity	
Intervention	group	 Control	group	
6MWD	(m)	 353	(116)	 388	(113)#	 374	(102)	 407	(105)#	 0.3	(-13	to	14)	 0.967	
Dyspnoea	post	6MWD	 5.4	(2.2)	 5.7	(2.3)	 5.5	(2.2)	 5.4	(2.1)	 0.2	(-0.3	to	0.8)	 0.400	
Leg	effort	post	6MWD	 4.2	(2.3)	 4.3	(2.0)	 4.3	(2.4)	 4.4	(2.0)	 -0.1	(-0.7	to	0.4)	 0.630	
Maximal	exercise	capacity	 Intervention	group	 Control	group	 	 	
Peak	work	rate	(W)	 54	(21)	 64	(26)#	 54	(20)	 59	(22)#	 5.2	(-0.4	to	10.8)	 0.069	
Peak	VO2	(mL/min)	 1,009	(310)	 1,048	(313)	 909	(275)	 966	(323)	 0.01	(-0.09	to	0.11)	 0.881	
Peak	VE	(L/min)	 36	(11)	 37	(11)	 38	(12)	 39	(15)	 -0.5	(-3.4	to	2.3)	 0.703	
Dyspnoea	post	CPET	 6.7	(2.6)	 6.3	(2.7)	 5.9	(2.3)	 6.4	(2.1)	 -0.5	(-1.4	to	0.5)	 0.324	
Leg	effort	post	CPET	 5.8	(2.9)	 6.0	(2.4)	 5.9	(2.2)	 6.1	(2.1)	 -0.1	(-1.0	to	0.8)	 0.836	
Endurance	exercise	
capacity	
Intervention	group		 Control	group		 	 	
Work	rate	(W)	 42	(16)	 44	(18)	 	 	
Endurance	cycle	time	(sec)	 271	(126)	 496	(309)#	 303	(163)	 466	(292)#	 75	(1	to	149)	 0.048	
Dyspnoea	post	cycle	test	 6.1	(2.2)	 6.0	(2.1)	 6.1	(2.2)	 5.9	(2.3)	 -0.3	(-1.0	to	0.4)	 0.405	
Leg	effort	post	cycle	test	 6.0	(1.9)	 5.2	(2.1)	#	 5.5	(2.3)	 5.5	(2.3)	 -0.4	(-1.2	to	0.3)	 0.216	
Dyspnoea	score	at	isotime	 6.1	(2.2)	 3.7	(1.3)#	 5.9	(2.0)	 4.4	(1.9)#	 -0.7	(-1.5	to	-0.01)	 0.049	
Leg	effort	score	at	isotime	 6.1	(1.9)	 4.2	(1.7)	#	 4.9	(2.3)	 4.5	(2.2)	 -0.9	(-1.7	to	0.01)	 0.052	
Data	are	presented	as	mean	(SD)	and	mean	(95%	CI).	Abbreviations:	6MWD	=	six	minute	walking	distance;	Peak	work	rate	=	
peak	 power	 output;	 W	 =	 watts;	 Peak	 VO2	 =	 peak	 oxygen	 uptake;	 Peak	 VE	 =	 peak	 pulmonary	 ventilation;	 CPET	 =	
cardiopulmonary	exercise	test.	Dyspnoea	and	leg	effort	scores	were	evaluated	with	the	modified	CR-10	Borg	scale.	Analyses	
are	based	on	169	(6MWD,	97%	of	completers),	92	(peak	work	rate,	53%	of	completers),	and	139	(endurance	cycle	time,	80%	
of	 completers)	 patients.	 #indicates	 a	 statistically	 significant	difference	within	 groups	 (p<0.05),	 *p-values	 are	 reported	 for	
between	group	comparisons	(ANCOVA	of	post-training	values	adjusted	for	baseline	values	as	covariates).	 	
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Table	3	Changes	in	respiratory	muscle	function	
Variables	
Intervention	group		 Control	group	 Adjusted	difference	
(95%	CI)	at	post	
training	
p-
value*	
Pre-	
training	
Post-
training	
Pre-
training	
Post-
training	
PImax	(cmH2O)	 53	(14)	 75	(19)
#	 52	(11)	 61	(13)#	 14	(10	to	18)	 <0.001	
PEmax	(cmH2O)	 110	(40)	 127	(52)
#	 104	(30)	 117	(35)#	 3	(-7	to	14)	 0.531	
Endurance	breathing	(sec)	 240	(108)	 593	(270)#	 251	(96)	 413	(236)#	 189	(114	to	265)	 <0.001	
Ti/Ttot	(%)	 31	(17)	 21	(14)#	 34	(19)	 28	(17)#	 -5.6	(-9.3	to	-1.9)	 0.003	
Total	work	(J)	 78	(83)	 258	(153)#	 79	(97)	 159	(162)#	 100	(57	to	142)	 <0.001	
Average	power	(W)	 1.8	(1.4)	 3.1	(1.7)#	 1.5	(1.5)	 2.1	(1.6)	#	 0.8	(0.4	to	1.1)	 <0.001	
Data	are	presented	as	mean	(SD)	and	mean	(95%	CI).	Abbreviations:	PImax	=	maximal	inspiratory	mouth	pressure;	PEmax	=	
maximal	expiratory	mouth	pressure;	Ti/Ttot	=	inspiratory	duty	cycle;	J	=	joules;	W	=	watts.	Analyses	are	based	on	174	(PImax,	
100%	of	completers)	patients.	#indicates	a	statistically	significant	within-group	difference	(p<0.05),	*p-values	are	reported	
for	between	group	comparisons	(ANCOVA	of	post-training	values	adjusted	for	baseline	values	as	covariates).	 	
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Figure	legends	
Figure	1	
A	diagram	summarizing	the	flow	of	participants	through	the	study.		
Figure	2	
Progression	 of	 total	 work	 performed	 during	 the	 inspiratory	 muscle	 training	 programme	 in	 the	
intervention	and	control	group,	*	p<	0.05	between	groups	based	on	a	two-way	ANOVA	analysis	with	
Bonferroni	corrections	of	post-hoc	tests,	values	represented	as	mean±SEM.	
Figure	3	
Relationships	of	training	quality	indices	(total	work	performed	per	IMT	session,	average	peak	power	
per	IMT	session;	panels	A-B),	and	training	intensity	(defined	as	inspiratory	load	(PI)	during	the	final	IMT	
sessions	expressed	as	%	of	baseline	PImax;	panel	C),	with	improvements	in	PImax.	Tertiles	based	on	
improvements	in	PImax	were	defined	as	follows:	1st	tertile:	∆PImax	≤	7	cmH2O	(n=56;	29%	intervention	
group	and	71%	control	group),	2nd	tertile	∆PImax	8-20	cmH2O	(n=60;	48%	intervention	group	and	52%	
control	group),	3rd	tertile:	∆PImax	≥	21	cmH2O	(n=55;	78%	intervention	group	and	22%	control	group).	
Data	are	presented	as	mean±SEM.	
Figure	4	
Relationships	between	improvements	in	PImax	and	cycling	training	load	during	the	last	week	of	general	
exercise	 training	 (panel	 A),	 6MWD	 (panel	 B),	 and	 endurance	 cycling	 time	 after	 training	 (panel	 C).	
Tertiles	based	on	improvements	in	PImax	were	defined	as	follows:	1st	tertile:	∆PImax	≤	7	cmH2O	(n=56;	
29%	 intervention	 group	 and	 71%	 control	 group),	 2nd	 tertile	 ∆PImax	 8-20	 cmH2O	 (n=60;	 48%	
intervention	group	and	52%	control	group),	3rd	tertile:	∆PImax	≥	21	cmH2O	(n=55;	78%	intervention	
group	and	22%	control	group).	Data	are	presented	as	mean±SEM.	




